Tagsold David, Toni Irmgard, Trollmann Regina, Woelfle Joachim, Gravou-Apostolatou Chara
Department of Pediatrics and Adolescent Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
Children (Basel). 2024 Feb 11;11(2):234. doi: 10.3390/children11020234.
This data analysis aimed to systematically analyze a pediatric patient population with a life-limiting disease who were administered cannabinoids. It was a retrospective single-center analysis of patients under supervision of the specialized outpatient pediatric palliative care (SOPPC) team at the Department of Pediatrics and Adolescent Medicine of the Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU). Thirty-one patients with a primary diagnosis of neuropediatric, oncologic, metabolic, and cardiologic categories were included. The indications we identified were spasticity, pain, restlessness, anxiety, loss of appetite, epilepsy, and paresis. Certain aspects of quality of life were improved for 20 of 31 patients (64.5%). For nine patients (29%), no improvement was detected. No conclusions could be drawn for two patients (6.5%). Adverse events were reported for six of the thirty-one patients (19.4%). These were graded as mild, including symptoms such as restlessness, nausea, and behavioral issues. We detected no clinically relevant interactions with other medications. We collected fundamental data on the use of cannabinoids by pediatric palliative patients. Cannabinoids are now frequently administered in pediatric palliative care. They seem to be safe to use and should be considered an add-on therapy for other drug regimens.
本数据分析旨在系统分析接受大麻素治疗的患有危及生命疾病的儿科患者群体。这是一项对在埃尔朗根 - 纽伦堡弗里德里希 - 亚历山大大学（FAU）儿科与青少年医学系专业门诊儿科姑息治疗（SOPPC）团队监督下的患者进行的回顾性单中心分析。纳入了31例初步诊断为神经儿科、肿瘤、代谢和心脏疾病类别的患者。我们确定的适应症包括痉挛、疼痛、躁动、焦虑、食欲不振、癫痫和轻瘫。31例患者中有20例（64.5%）生活质量的某些方面得到改善。9例患者（29%）未检测到改善。2例患者（6.5%）无法得出结论。31例患者中有6例（19.4%）报告了不良事件。这些不良事件被评为轻度，包括躁动、恶心和行为问题等症状。我们未检测到与其他药物的临床相关相互作用。我们收集了儿科姑息治疗患者使用大麻素的基础数据。大麻素目前在儿科姑息治疗中经常使用。它们似乎使用安全，应被视为其他药物治疗方案的附加疗法。
